{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:59Z","timestamp":1740143999574,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40258-019-00545-9","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T02:02:26Z","timestamp":1578621746000},"page":"477-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Do Research Groups Align on an Intervention\u2019s Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-6278","authenticated-orcid":false,"given":"Matthew","family":"Sussman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Menzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"545_CR1","unstructured":"CVS Health. Current and new approaches to making drugs more affordable. Updated August 2018. https:\/\/cvshealth.com\/sites\/default\/files\/cvs-health-current-and-new-approaches-to-making-drugs-more-affordable.pdf. Accessed 16 Feb 2019."},{"key":"545_CR2","unstructured":"Institute for Clinical and Economic Review. The Institute for Clinical and Economic Review to Collaborate with the Department of Veteran Affairs\u2019 Pharmacy Benefits Management Services Office. Updated June 27, 2017. https:\/\/icer-review.org\/announcements\/va-release\/. Accessed 16 Feb 2019."},{"key":"545_CR3","unstructured":"Robinson JC. Amgen Cuts Repatha\u2019s Price By 60% Will Value-based Pricing Support Value-based Patient Access? Health Affairs. Updated November 28, 2018. https:\/\/www.healthaffairs.org\/do\/10.1377\/hblog20181127.943927\/full\/. Accessed 16 Feb 2019."},{"key":"545_CR4","unstructured":"Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. https:\/\/icer-review.org\/material\/high-cholesterol-final-report\/. Accessed 20 Nov 2019."},{"key":"545_CR5","unstructured":"Institute for Clinical and Economic Review. About. https:\/\/icer-review.org\/about\/. Accessed 16 Feb 2019."},{"key":"545_CR6","unstructured":"Institute for Clinical and Economic Review. Final value assessment framework for 2017\u20132019. https:\/\/icer-review.org\/final-vaf-2017-2019\/. Accessed 16 Feb 2019."},{"key":"545_CR7","unstructured":"Dubois, RW. From the Editorial Board: Robert W. Dubois, MD, PhD. Am J Manag Care. 2019;25(7):302. https:\/\/www.ajmc.com\/journals\/issue\/2019\/2019-vol25-n7\/from-the-editorial-board-robert-w-dubois-md-phd. Accessed 15 Aug 2019."},{"key":"545_CR8","unstructured":"Center for the Evaluation of Value and Risk in Health. CEA Registry. https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry. Accessed 25 Mar 2019."},{"key":"545_CR9","unstructured":"Institute for Clinical and Economic Review. Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. https:\/\/icer-review.org\/material\/cgrp-final-report\/. Accessed 20 Nov 2019."},{"issue":"10","key":"545_CR10","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644\u201357.","journal-title":"Cephalalgia"},{"key":"545_CR11","unstructured":"Institute for Clinical and Economic Review. Targeted immune modulators for rheumatoid arthritis: effectiveness & value. https:\/\/icer-review.org\/material\/ra-final-report\/. Accessed 20 Nov 2019."},{"key":"545_CR12","unstructured":"Institute for Clinical and Economic Review. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness & value. https:\/\/icer-review.org\/material\/ms-final-report\/. Accessed 20 Nov 2019."},{"key":"545_CR13","unstructured":"Institute for Clinical and Economic Review. Treatment options for advanced non-small cell lung cancer: effectiveness, value, and value-based price benchmarks. https:\/\/icer-review.org\/material\/nsclc-final-report\/. Accessed 20 Nov 2019."},{"key":"545_CR14","unstructured":"Institute for Clinical and Economic Review. Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks. https:\/\/icer-review.org\/material\/mm-final-report\/. Accessed 20 Nov 2019."},{"key":"545_CR15","unstructured":"Institute for Clinical and Economic Review. CardioMEMS HF System (St. Jude Medical, Inc.) and sacubitril\/valsartan (Entresto, Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. https:\/\/icer-review.org\/material\/chf_final_report\/. Accessed 20 Nov 2019."},{"issue":"12","key":"545_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2165\/00019053-200624120-00006","volume":"24","author":"JR Spalding","year":"2006","unstructured":"Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-\u03b1 inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics. 2006;24(12):1221\u201332.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"545_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0002-9343(02)01243-3","volume":"113","author":"JB Wong","year":"2002","unstructured":"Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54\u00a0weeks of infliximab for rheumatoid arthritis. Am J Med. 2002;113(5):400\u20138.","journal-title":"Am J Med"},{"issue":"1","key":"545_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3111\/13696990903508021","volume":"13","author":"Y Yuan","year":"2010","unstructured":"Yuan Y, Trivedi D, Maclean R, et al. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ. 2010;13(1):33\u201341.","journal-title":"J Med Econ"},{"issue":"9","key":"545_CR19","first-page":"1745","volume":"35","author":"M Vera-Llonch","year":"2008","unstructured":"Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-\u03b1 antagonists. J Rheumatol. 2008;35(9):1745\u201353.","journal-title":"J Rheumatol"},{"issue":"3","key":"545_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.18553\/jmcp.2007.13.3.245","volume":"13","author":"C Bell","year":"2007","unstructured":"Bell C, Graham J, Earnshaw S. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245\u201361.","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"545_CR21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.clinthera.2012.07.010","volume":"34","author":"F Pan","year":"2012","unstructured":"Pan F, Goh JW, Cutter G, et al. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clin Ther. 2012;34(9):1966\u201376.","journal-title":"Clin Ther"},{"issue":"2","key":"545_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF03256144","volume":"7","author":"SR Earnshaw","year":"2009","unstructured":"Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009;7(2):91\u2013108.","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"545_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/annonc\/mdx305","volume":"28","author":"PN Aguiar Jr","year":"2017","unstructured":"Aguiar PN Jr, Perry LA, Penny-Dimri J, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017;28(9):2256\u201363.","journal-title":"Ann Oncol"},{"issue":"8","key":"545_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","volume":"35","author":"M Huang","year":"2017","unstructured":"Huang M, Lou Y, Pellissier J. Cost effectiveness of Pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics. 2017;35(8):831\u201344.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"545_CR25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","volume":"19","author":"AJ Jakubowiak","year":"2016","unstructured":"Jakubowiak AJ, Campioni M, Benedict \u00c1, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061\u201374.","journal-title":"J Med Econ"},{"issue":"6","key":"545_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/clc.22535","volume":"39","author":"SR Gandra","year":"2016","unstructured":"Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313\u201320.","journal-title":"Clin Cardiol"},{"issue":"5","key":"545_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","volume":"4","author":"JB King","year":"2016","unstructured":"King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392\u2013402.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"545_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","volume":"1","author":"TA Gaziano","year":"2016","unstructured":"Gaziano TA, Fonarow GC, Claggett B, Chan WW, et al. Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1(6):666\u201372.","journal-title":"JAMA Cardiol"},{"key":"545_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"545_CR30","unstructured":"Science & Innovation Theater. (2019). ICER: payer perspectives on the use and usage of ICER reports [PowerPoint slides]. https:\/\/www.amcp.org\/Resource-Center\/formulary-utilization-management\/icer-payer-perspectives-use-and-usage-icer-reports."},{"key":"545_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38737.607558.80","author":"CM Bell","year":"2006","unstructured":"Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006. https:\/\/doi.org\/10.1136\/bmj.38737.607558.80.","journal-title":"BMJ"},{"key":"545_CR32","unstructured":"Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: what we know, what we have yet to learn. World Health Organization and Health Action International; 2005."},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","volume":"326","author":"J Lexchin","year":"2003","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: a systematic review. BMJ. 2003;326:1167\u201370.","journal-title":"BMJ"},{"issue":"2","key":"545_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1377\/hlthaff.19.2.92","volume":"19","author":"PJ Neumann","year":"2000","unstructured":"Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff. 2000;19(2):92\u2013109.","journal-title":"Health Aff"},{"issue":"1","key":"545_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jama.290.1.113","volume":"290","author":"SS Chopra","year":"2003","unstructured":"Chopra SS. Industry funding of clinical trials: benefit or bias? JAMA. 2003;290(1):113\u20134.","journal-title":"JAMA"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-019-00545-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00545-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T02:13:37Z","timestamp":1610158417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-019-00545-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s40258-019-00545-9","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"10 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matthew Sussman, Jeffrey C. Yu, and Joseph Menzin declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}